Study of Combivir for Patients With Primary Biliary Cirrhosis

Inclusion Criteria: * Patients 18 years old of either sex will be recruited for this study. * Persistently elevated alkaline phosphatase or serum aminotransferases of at least 1.5 times normal after a minimum of 6 months UDCA therapy. * Positive serum AMA (titer \> 1:20). * Liver biopsy histology compatible with PBC obtained at any time prior to study. * Maintained on UDCA at a dose of 13-15 mg/kg for 6 or more months. * Patients must read and sign informed consent form. Exclusion Criteria: * Patients treated with immunosuppressive or anti-inflammatory agents such as colchicine, methotrexate, D-penicillamine, cyclosporine, tacrolimus, mycophenolate mofetil, corticosteroid therapy will be excluded but may enter the study after a 3 month period off immunosuppressive and anti-inflammatory therapy. * Advanced liver disease: Childs Pugh class B or C cirrhosis, recurrent variceal hemorrhage, spontaneous encephalopathy, diuretic resistant ascites, need for liver transplantation within the year. * Patients with a secondary hepatic diagnosis such as viral hepatitis, drug induced liver injury, extrahepatic biliary obstruction, primary sclerosing cholangitis, metabolic liver diseases or alcoholic liver disease. * Regular use of more than 30 g of alcohol per day in the last year. * Patients with a predicted survival of less than 3 years from malignant or other potentially life threatening disease. * Creatinine clearance less than \< 70 mL/min using the Cockcroft Gault equation: * Clinically apparent pancreatitis. * Serum amylase \> 3 x upper limit of normal (patients with sicca syndrome and salivary gland disease may have elevated amylase levels) * Pregnancy or breast-feeding a child. * Sexually active patients of child bearing age and not using effective contraception. * Allergic reaction to Combivir like drugs * Clinical evidence of myositis * Weight of \< 50 Kg